Jefferson University Hospitals

Provider Profile

Rita S. Axelrod, MD

Jefferson University Physician

Academic Title: Professor
Co-Director, Thoracic Oncology Program

Medical Oncology
Medical Oncology - Head & Neck Cancer
Medical Oncology - Lung Cancer

Make An Appointment

Click to call 1-800-JEFF-NOW (800-533-3669) or

Office Locations

925 Chestnut Street
Suite 320A
Philadelphia PA 19107
Phone: (215) 955-8874
Fax: (215) 503-7697

Medical Services

Years in Practice


Board Certifications

  • Internal Medicine
  • Medical Oncology
  • Hematology

Hospital Affiliation / Admitting Privileges

  • Thomas Jefferson University Hospital
  • Methodist Hospital Division of Thomas Jefferson University Hospital

Awards and Honors

Philadelphia Magazine's Top Docs 2016,2015,2014,2013,2012,2011,2010


  • New York University School of Medicine, Medical School


  • St. Luke's/Roosevelt Hospital, New York


  • Medical College of Georgia


  • Lankenau Hospital
  • Philadelphia General Hospital

Jefferson physicians accept most health insurance plans, including those listed below. However, plan acceptance may vary by practice and may be subject to change. If you have questions about whether a specific physician accepts your insurance, please contact your insurance company.

Insurances Accepted

  • Aetna
  • Aetna PA Employee Benefit Trust Fund (PEBTF)
  • Amer Assoc Retired Persons (AARP)
  • AmeriHealth
  • Amerihealth Caritas
  • AmeriHealth Comprehensive
  • AmeriHealth HMO
  • AmeriHealth Major Medical
  • AmeriHealth Personal Choice
  • BC BS Special Care
  • Blue Choice
  • Blue Cross/Blue Shield
  • Blue Cross/Blue Shield of Delaware
  • Cigna Healthspring
  • Cigna PPO, POS
  • Consumer Health Network PPO
  • CorVel
  • Coventry/Health America
  • Delaware Blue Cross/Blue Shield
  • Devon
  • Empire BC/BS
  • Employers Health Network PPO
  • Evolutions (Guardian Resources)
  • Federal BCBS
  • First Health Network
  • Galaxy
  • Geisinger Health Plan
  • Health America PPO
  • Health Management Network PPO
  • Horizon Blue Cross/Blue Shield
  • Horizon HMO
  • HumanaChoicePPO,Medicare,GoldPlusHMO
  • Inter-County Health Plan
  • Intergroup Preferred
  • Jeff Plus
  • Keystone 65 HMO
  • Keystone First VIP Choice
  • Keystone First/Connect
  • Keystone Health Plan East
  • Medallion of New Jersey
  • Medicaid of PA
  • Medicare
  • Mercy LIFE
  • MultiPlan Inc.
  • NJ Blue Shield
  • NJ Plus
  • Oxford of PA
  • Personal Choice (GPPPN)
  • Personal Choice 65
  • PlanCare America
  • Postal Workers/Mailhandlers
  • PPO Next
  • Preferred Care PPO
  • Premier Blue
  • Prime Health Services, Inc.
  • Private Healthcare Systems (PHCS)
  • Qualcare
  • Tricare
  • United Healthcare
  • UPMC HMO,PPO ReadingHspEmpONLY
  • UPMC Medicare HMO
  • US Family Health Plan

Recent Publications

Not All Head and Neck Squamous Cell Carcinomas Are Created Equal: Some Are More Aggressive

Neutrophil to lymphocyte ratio associated with prognosis of lung cancer

Quality of Life and Performance Status From a Substudy Conducted Within a Prospective Phase 3 Randomized Trial of Concurrent Accelerated Radiation Plus Cisplatin With or Without Cetuximab for Locally Advanced Head and Neck Carcinoma: NRG Oncology Radiation Therapy Oncology Group 0522

The KRAS-variant and cetuximab response in head and neck squamous cell cancer a secondary analysis of a randomized clinical trial

PARTNER: An open-label, randomized, phase 2 study of docetaxel/cisplatin chemotherapy with or without panitumumab as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck

Correlation Between the Severity of Cetuximab-Induced Skin Rash and Clinical Outcome for Head and Neck Cancer Patients: The RTOG Experience

Phase I Trial Using Induction Ciplatin, Docetaxel, 5-FU and Erlotinib Followed by Cisplatin, Bevacizumab and Erlotinib With Concurrent Radiotherapy for Advanced Head and Neck Cancer

Journal of clinical oncology

Randomized phase II study of carboplatin and paclitaxel with either linifanib or placebo for advanced nonsquamous non-small-cell lung cancer

Modeling the overall survival of patients with advanced-stage non-small cell lung cancer using data of routine laboratory tests

Treatment-related acute esophagitis for patients with locoregionally advanced non-small cell lung cancer treated with involved-field radiotherapy and concurrent chemotherapy

Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522

E5501: Phase II study of topotecan sequenced with etoposide/cisplatin, and irinotecan/cisplatin sequenced with etoposide for extensive-stage small-cell lung cancer

Current management of locally advanced head and neck cancer: The combination of chemotherapy with locoregional treatments

A pilot study of hypofractionated stereotactic radiation therapy and sunitinib in previously irradiated patients with recurrent high-grade glioma

Sarcoidosis mimicking metastatic bone disease in head and neck cancer

Identification of a KRAS mutation in a patient with non-small cell lung cancer treated with chemoradiotherapy and panitumumab

The addition of amifostine to carboplatin and paclitaxel based chemoradiation in locally advanced non-small cell lung cancer: Long-term follow-up of Radiation Therapy Oncology Group (RTOG) randomized trial 9801

An economic model to value companion diagnostics in non-small-cell lung cancer

Treatment-related acute esophagitis for patients with locoregionally advanced non-small cell lung cancer treated with involved-field Radiotherapy and concurrent chemotherapy